Dr. Siegel is an Assistant Member in the Department of Cancer Epidemiology at the H. Lee Moffitt Cancer Center and Research Institute. Her research has focused on discovering novel cancer biomarkers of early detection and progression. She has a primary interest in HPV related disease and has investigated epigenetic biomarkers of cancer risk and HPV infection and factors associated with HPV persistence and clearance. As an epidemiologist, she has experience conducting molecular epidemiological studies focused on HPV, cervical dysplasia and cancer risk. In addition, she directs a Molecular Epidemiology laboratory and has over ten years of molecular biology laboratory expertise. She has established and maintained the Bisulfite Genomic Sequencing technique, quantitative Methylation Specific PCR (QMSP), and pyrosequencing in her laboratory. She is NCI-funded to evaluate DNA methylation patterns in cervical cancers utilizing archived formalin fixed paraffin embedded specimens. Since 2004, she has collaborated in colorectal, esophageal and anal cancer outcomes research and has co-authored manuscripts in this area. She is a co-investigator evaluating the quality of care in the treatment of colorectal, breast and lung cancers throughout the state of Florida (PI Jacobsen). Moreover, she was awarded funding to establish the ColoCare Moffitt Site. This pilot grant provides funding to complement TCC by collecting detailed exposure and health behaviors on 150 TCC colon cancer patients, including anthropometrics and quality of life. This feasibility study is providing the foundation for several additional proposed studies. Additionally, Dr. Siegel has collaborated in colorectal, esophageal and anal cancer outcomes research. She leads, as PI, a small cohort study examining the association between IGF/insulin and anthropometrics and colon cancer outcomes.